Management of New-Onset Atrial Fibrillation

Patient Selection for Hospital Admission

The American Heart Association recommends admitting patients with new-onset atrial fibrillation if they present with hemodynamic instability, acute coronary syndrome, decompensated heart failure, or significant concurrent illness requiring hospitalization 2, 3
Patients with pre-excitation syndromes, such as Wolff-Parkinson-White, and rapid ventricular rates require specialized management and hospital admission 1

The American College of Cardiology recommends using beta-blockers or non-dihydropyridine calcium channel blockers as the preferred agents for acute rate control in patients with new-onset atrial fibrillation 1
Metoprolol, diltiazem, and verapamil are commonly used medications for rate control, with specific dosing recommendations: metoprolol 2.5-5 mg IV over 2 minutes, diltiazem 0.25 mg/kg IV over 2 minutes, and verapamil 5-10 mg IV over 2 minutes 3

The American Heart Association recommends initiating anticoagulation immediately for patients with a CHA₂DS₂-VASc score ≥2, unless contraindicated, with direct oral anticoagulants (DOACs) preferred over warfarin 1, 4
For patients with a CHA₂DS₂-VASc score of 1, anticoagulation should be considered based on individual risk factors 4

Urgent cardioversion is indicated for patients with hemodynamic instability, ongoing myocardial ischemia, or inadequate rate control despite medications 2, 1
Elective cardioversion requires 3 weeks of therapeutic anticoagulation before cardioversion, or transesophageal echocardiography to rule out left atrial thrombus, followed by short-term anticoagulation 5, 6

Patients discharged from the emergency department should have achieved rate control, be initiated on DOAC with appropriate dosing, and have a plan for follow-up within 48-72 hours 1, 4